Brian McNamara, a former Novartis executive, has been named chief executive designate of a new consumer healthcare company to be demerged from GlaxoSmithKline Plc in 2022. He is currently head of the predecessor company, a joint venture between GSK and Pfizer Inc. Mr McNamara joined GSK in 2015 from Novartis where he was head of over-the-counter medicines. He began his career at Procter & Gamble Co of the US in product supply and brand marketing.
Mr McNamara holds a degree in electrical engineering from Union College in Schenectady, New York and a masters of business administration in finance from the University of Cincinnati, both in the US.
GSK announced the appointment on 22 July 2021